Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-06-21Clinical Trial Update: Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
A multicenter registry examining treatments and outcomes for patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2016-04-01Clinical Trial Update: Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 study evaluating SAR245409 in combination with rituximab or bendamustine plus rituximab in patients with indolent non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
A completed clinical trial update evaluating Ribomustin (bendamustine) as second-line therapy for relapsed or refractory indolent B-cell non…
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Rituximab-Gemcitabine/Oxaliplatin in relapsed indolent non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2015-06-22Clinical Trial Update: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating rituximab in patients with low tumor burden indolent non-Hodgkin's lymphoma has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) [Phase 1, Phase 2]
This report summarizes the completion and results posting of a Phase 1/2 trial evaluating Bendamustine plus Bortezomib in indolent non-Hodgk…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 dose-ranging study evaluated pixantrone in the FND-R regimen for indolent non-Hodgkin lymphoma; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2014-12-30Clinical Trial Update: Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating the efficacy and safety of SH-L-749 in indolent B-cell non-Hodgk…
-
CLINICAL_TRIALS trial_result · 2014-10-16Clinical Trial Update: Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial of bendamustine hydrochloride for indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia completed, with results pos…
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
A trial evaluating a Biaxin (clarithromycin)-based antibiotic regimen for previously untreated, advanced-stage indolent lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2014-06-25Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma [Phase 3]
Phase 3 trial evaluating rituximab alone and in combination with Roferon-A (interferon alfa) in follicular and other CD20+ indolent lymphoma…
-
CLINICAL_TRIALS trial_result · 2014-06-20Clinical Trial Update: Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant [Phase 2]
A Phase 2 trial evaluating low-intensity conditioning for allogeneic stem cell transplantation in multiple myeloma, chronic lymphocytic leuk…
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab [Phase 3]
Phase 3 trial assessing the safety and efficacy of Treanda (bendamustine HCl) in patients with indolent non-Hodgkin lymphoma refractory to r…
-
CLINICAL_TRIALS trial_result · 2013-10-14Clinical Trial Update: Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 clinical trial update reports results for lenalidomide (Revlimid) in patients with relapsed or refractory indolent non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2013-06-26Clinical Trial Update: Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial of Dolastatin 10 in patients with indolent non-Hodgkin lymphoma, Waldenström's macroglobulinemia, or chronic lymphocytic leuke…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: Lenalidomide Plus Rituximab (R) in Non Follicular NHL [Phase 2]
Phase 2 trial update of lenalidomide plus rituximab in indolent non-Hodgkin lymphoma; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2013-01-28Clinical Trial Update: A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluated escalating doses of PRO131921 in patients with indolent non-Hodgkin lymphoma to assess safety and pre…
-
CLINICAL_TRIALS trial_result · 2012-08-13Clinical Trial Update: Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Tositumomab with I-131-tositumomab in patients with relapsed indolent non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2012-07-04Clinical Trial Update: Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma [Phase 2]
This report describes a Phase 2 trial of the radioimmunotherapy combination Tositumomab with Iodine-131 for previously untreated, advanced-s…
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies [Phase 2]
Phase 2 trial of SB1518 in advanced lymphoid malignancies assessed safety and efficacy in Hodgkin lymphoma, mantle cell lymphoma, and indole…
-
CLINICAL_TRIALS trial_result · 2011-07-13Clinical Trial Update: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas [Phase 1, Phase 2]
Clinical trial update for a Phase 1-2 open-label study of AEG35156 in relapsed or refractory chronic lymphocytic leukemia and indolent B-cel…
-
CLINICAL_TRIALS trial_result · 2010-02-24Clinical Trial Update: Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating the combination of bryostatin and fludarabine in patients with chronic lymphocytic leukemia or relapsed indolent no…
-
CLINICAL_TRIALS trial_result · 2009-09-18Clinical Trial Update: Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. [Phase 2]
Phase 2 trial evaluating Fludarabine, Cyclophosphamide, and Rituximab followed by Zevalin in indolent non-Hodgkin lymphoma; the study status…